Pharma Bavaria International is expanding the territory of its brand Combofusiv™ (AFT’s Maxigesic® IV) to Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay by signing an extension of a license agreement with the New Zealand based company AFT Pharmaceuticals. The contract covers meanwhile a total of 17 countries, after both companies had already entered into the initial agreement in Feb 2020 for Central America and the Caribbean. Latin America is one of Pharma Bavaria’s focus growth regions.
Combofusiv™/(Maxigesic®) IV (Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) has been developed by AFT as an intravenous formulation, for use in post-operative pain management; also sparing opioids. A major Phase 3 clinical trial conducted in Texas and Maryland USA found that Combofusiv™ / (Maxigesic IV) provided significantly better pain relief than either paracetamol IV or ibuprofen IV alone in the same doses.*
AFT Pharmaceuticals Chief Executive Dr. Hartley Atkinson comments: “We are delighted to extend our agreement with Pharma Bavaria. Latin American markets are significant and growing with one recent report suggesting the market for pain management medicines would grow at an average rate of 3.5% a year until 2027**.”
Pharma Bavaria’s Chief Executive Officer Dr. Manuel Heim says: “We are very excited to extend our excellent collaboration with AFT to further territories in the LATAM region with this innovative formulation; giving healthcare professionals new options in hand for successful pain management. Combofusiv™ IV is a consequent add-on to our existing portfolio, strengthening our focus in the therapeutic area of analgesics with an added-value.”
Gagan Datta, Pharma Bavaria’s Chief Commercial Officer notes: “Combofusiv™ clearly underlines our ambitions to further grow in these markets with an excellent speciality product. This is the first Paracetamol/Ibuprofen injectable in the region and is therefore an excellent option to expand our position in the segment. I am very confident, it will be of great value to healthcare professionals, in their advancing treatment schemes.”
About Pharma Bavaria International
Pharma Bavaria International Group distributes and promotes high-quality pharmaceuticals with well-researched ingredients in more than 45 countries under its own brand. With a strong focus on growth regions such as the Middle East, Africa, South-East Asia, and LATAM and other emerging economies Pharma Bavaria’s portfolio of prescription medicines includes anti-infectives, analgesics/ anti-allergic/ anti-inflammatory, flu and cold, gastroenterology, oncology, cardiology, and women’s healthcare brands and is rounded up with a range of OTC products. For more information visit: www.pharma-bavaria.com
For more information, please contact: Dr. Manuel Heim, Managing Director, Pharma Bavaria International GmbH e-mail: email@example.com
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. AFT’s product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. AFT’s business model is to develop and in-license products for sale by their own dedicated sales teams in Australia, New Zealand and in certain Southeast Asian markets, and to out-license their products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit: www.aftpharm.com
*Daniels SE et al. Efficacy and safety of an IV acetaminophen/ibuprofen combination after bunionectomy. A randomized, double-blind, factorial, placebo-controlled trial. Submitted for publication.
** “LATAM Pain Management Drugs Market by Drug Class, Indication: Regional Opportunity Analysis and Industry Forecast, 2019-2027 (https://www.globenewswire.com/news-release/2020/12/14/2144692/0/en/Insights-on-the-Pain-Management-Drugs-LATAM-Market-to-2027-Opportunity-Analysis-and-Industry-Forecast.html)